Genito Urinary System and Sex Hormones sales in Sweden experienced fluctuations from 2013 to 2023, starting at 1.73 Billion SEK in 2013 and reaching 1.86 Billion SEK in 2023. The market saw year-on-year variations, ranging from a decrease of 2.56% in 2014 to a noteworthy growth of 5.29% in 2022. The Compound Annual Growth Rate (CAGR) over the last five years from 2018 to 2023 stands at 1.35%, indicating a moderate growth trend.
Looking ahead, from 2024 to 2028, the forecasted sales show a steady but slow increase, with a forecasted CAGR of 0.18%, culminating at 1.88 Billion SEK in 2028. The average annual growth rate for the forecasted period is projected to be 0.9%.
Future trends to watch for include advancements in genito-urinary treatments and sex hormone replacement therapies, demographic shifts such as an aging population, healthcare policy changes, and ongoing innovation in pharmaceuticals that could impact market demand.
